48
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Properties of Chimeric Prostacyclin/Prostaglandin D2 Receptors: Site‐Directed Mutagenesis Reveals the Significance of the Isoleucine Residue at Position 323

, , , , &
Pages 83-97 | Published online: 28 Feb 2003
 

Abstract

Mouse prostacyclin (mIP) receptors transiently expressed in Chinese hamster ovary (CHO) cells activated both adenylyl cyclase and phospholipase C, with a 33‐fold preference for signaling through Gs. The prostacyclin (IP) receptor agonists cicaprost, iloprost, carbacyclin, and prostaglandin E1 showed a similar order of potency for activation of both signaling pathways in cells transiently transfected with the mIP and the chimeric prostacyclin/prostaglandin D2 (IPN‐VII/DPC and IPN‐V/DPVI‐C) receptors. Substitution of the carboxyl‐terminal tail of the prostacyclin receptor with the corresponding region of the mDP receptor (IPN‐VII/DPC) produced a receptor with increased coupling to both Gs and Gq. However, this increased G‐protein coupling was lost in the IPN‐V/DPVI‐C receptor. The observation that both these chimeric receptors can activate phospholipase C indicates that the carboxyl‐terminal tail of the IP receptor is not entirely responsible for its ability to couple to Gq. Site‐directed mutagenesis studies suggest that isoleucine at position 323 in the IPN‐VII/DPC receptor plays an important role in mediating the increased potency of this chimeric receptor.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.